Interstitial Lung Disease Unit, Royal Brompton and Harefield National Health Service (NHS) Foundation Trust, London, UK; Department of Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, London, UK.
Department of Lung Transplantation, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK; Department of Interstitial Lung Disease, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
Lancet Respir Med. 2019 Mar;7(3):271-282. doi: 10.1016/S2213-2600(18)30502-2. Epub 2019 Feb 6.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Lung transplantation is the only intervention shown to increase life expectancy for patients with IPF, but it is associated with disease-specific challenges. In this Review, we discuss the importance of a proactive approach to the management of IPF comorbidities, including gastro-oesophageal reflux, pulmonary hypertension, coronary artery disease, and malignancy. With a donor pool too small to meet demand and unacceptably high mortality on transplant waiting lists, we discuss different systems used internationally to facilitate organ allocation. We explore the rapidly evolving landscape of transplantation for patients with IPF with regards to antifibrotic therapy, technological advances in extracorporeal life support, advances in understanding of the genetics of the disease, and the importance of a holistic multidisciplinary approach to care. Finally, we consider potential advances over the next decade that are envisaged to improve transplantation outcomes in patients with advanced IPF.
特发性肺纤维化(IPF)是一种预后不良的进行性肺部疾病。肺移植是唯一被证明可以延长 IPF 患者预期寿命的干预措施,但它与特定于疾病的挑战有关。在这篇综述中,我们讨论了积极管理 IPF 合并症的重要性,包括胃食管反流、肺动脉高压、冠状动脉疾病和恶性肿瘤。由于供体池太小,无法满足需求,移植等待名单上的死亡率高得令人无法接受,我们讨论了国际上用于促进器官分配的不同系统。我们探讨了针对 IPF 患者的移植领域的快速发展,包括抗纤维化治疗、体外生命支持技术的进步、对疾病遗传的理解的进步,以及整体多学科护理的重要性。最后,我们考虑了未来十年预计将改善晚期 IPF 患者移植结果的潜在进展。